Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Operating activities    
Net loss $ (40,773) $ (23,814)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 339 309
Stock-based compensation expense 5,062 2,961
Write-off of deferred financing costs 312  
Net accretion and amortization of investments in marketable securities 426 (306)
Changes in assets and liabilities:    
Interest receivable and other current assets 178 478
Prepaid research and development expenses and other prepaid assets (2,793) 6,510
Other assets (1,240) 0
Accounts payable 798 (2,027)
Accrued liabilities (2,084) (6,568)
Net cash used in operating activities (39,775) (22,457)
Investing activities    
Purchases of property and equipment (87) 0
Purchases of marketable securities (33,820) (65,504)
Proceeds from maturities of marketable securities 78,280 159,136
Net cash provided by investing activities 44,373 93,632
Financing activities    
Proceeds from issuance of common stock pursuant to equity award plans 106 7
Net cash provided by financing activities 106 7
Net increase in cash and cash equivalents 4,704 71,182
Cash and cash equivalents at beginning of period 28,193 24,869
Cash and cash equivalents at end of period 32,897 96,051
Supplemental disclosure    
Cash paid for amounts included in the measurement of lease liabilities 332 323
Supplemental non-cash investing and financing activities    
Accrued financing costs 93 $ 205
Accrued financing costs in accounts payable $ 21